MabThera (rituximab) 500 mg/50 mL concentrate for solution for infusion (Roche, Germany) — original MabThera (rituximab) Targeted cancer therapy. Delivery from Europe within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415.

Interchangeable drugs with the same active ingredient:

• MabThera
• Reditux
• Rituxim
• Acellbia

Indications.

• Mabthera® is indicated for adults in the following cases:
• Non-Hodgkin's lymphoma
• Monotherapy for patients with stage III-IV follicular lymphoma who are resistant to chemotherapy or are in the stage of second or subsequent relapses after chemotherapy.
• Treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with chemotherapy according to the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisolone).
• Treatment of previously untreated stage III-IV follicular lymphoma in combination with Chemotherapy.
• Maintenance therapy for follicular lymphomas after response to induction therapy.
• Chronic
• Treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia in combination with chemotherapy. There are limited data on the efficacy and safety of use in patients previously treated with monoclonal antibodies, including MabThera ®, or in patients refractory to previous treatment with MabThera ®® plus chemotherapy.

• rheumatoid arthritis
• Treatment of severe rheumatoid arthritis (active form) in adults in combination with methotrexate when treatment with other disease-modifying antirheumatic drugs (DMARDs) is ineffective or intolerable, including treatment with one or more tumor necrosis factor inhibitors.
• When used in combination with methotrexate, MabThera® reduces the rate of progression of destructive changes in joints as measured by radiographic data and improves physical function.
• Granulomatosis with polyangiitis and microscopic polyangiitis
• Treatment of severe forms of active granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis in combination with corticosteroids to induce remission in adult patients
•